Insider Transactions in Q1 2022 at Teva Pharmaceutical Industries LTD (TEVA)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 09
2022
|
Richard Daniell Exec. VP, European Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
13,135
+28.22%
|
-
|
|
Feb 09
2022
|
Sven Dethlefs EVP, North America Commercial |
SELL
Open market or private sale
|
Direct |
4,138
-4.54%
|
$37,242
$9.06 P/Share
|
|
Feb 09
2022
|
Sven Dethlefs EVP, North America Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
13,135
+12.6%
|
-
|
|
Feb 09
2022
|
Eric Drape Executive VP Global Operations |
SELL
Open market or private sale
|
Direct |
3,583
-9.03%
|
$32,247
$9.06 P/Share
|
|
Feb 09
2022
|
Eric Drape Executive VP Global Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
6,568
+14.2%
|
-
|
|
Feb 09
2022
|
Hafrun Fridriksdottir Executive VP, Global R&D |
SELL
Open market or private sale
|
Direct |
6,116
-10.63%
|
$55,044
$9.06 P/Share
|
|
Feb 09
2022
|
Hafrun Fridriksdottir Executive VP, Global R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
16,121
+21.89%
|
-
|
|
Feb 09
2022
|
Mark Sabag EVP, International Markets |
BUY
Exercise of conversion of derivative security
|
Direct |
15,523
+17.34%
|
-
|
|
Feb 09
2022
|
Kare Schultz President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
26,867
+2.46%
|
-
|
|
Feb 09
2022
|
David Matthew Stark Exec. VP Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
6,110
-39.39%
|
$54,990
$9.06 P/Share
|
|
Feb 09
2022
|
David Matthew Stark Exec. VP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,538
+44.7%
|
-
|